Denosumab Dosing and Supplementation Guidelines

Supplementation Requirements

The American Society of Clinical Oncology recommends calcium intake of 1000-1200 mg per day and vitamin D supplementation of 1000-2000 IU daily for patients receiving treatments that adversely affect bone health 1

Denosumab is an appropriate option for patients who have failed or are intolerant to other osteoporosis therapies, such as oral bisphosphonates, according to clinical guidelines 2
The 60 mg every 6 months dosing schedule has been shown to effectively reduce fracture risk in multiple clinical trials, including the FREEDOM trial 3, 4

The FREEDOM trial demonstrated that denosumab significantly reduced the risk of new vertebral fractures (2.3% vs 7.2%; RR, 0.32) compared to placebo over 36 months, with a strength of evidence supported by multiple clinical trials 3
Long-term extension of the FREEDOM trial observed patients for up to 10 years of denosumab therapy with continued fracture risk reduction, indicating a high level of evidence for long-term efficacy 3

Clinical trials have reported common adverse effects of denosumab, including arthralgia, nasopharyngitis, headache, extremity pain, upper respiratory infection, constipation, urinary tract infection, and rash, with a similar rate of serious adverse events between denosumab and placebo groups (23.8% vs 23.9%) 3
Osteonecrosis of the jaw (ONJ) is a rare but serious potential complication, particularly at higher doses used for cancer treatment, with a low level of evidence due to its rare occurrence 5